Nuvectis Pharma, Inc. NVCT Income Statement
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| $18.15M+40.5% | $12.92M-16.0% | $15.38M+16.3% | $13.23M+38.6% | ||
| $9.42M+36.0% | $6.93M-7.8% | $7.52M+25.1% | $6.01M+79.4% | ||
| -$27.57M-38.9% | -$19.85M+13.3% | -$22.9M-19.0% | -$19.23M-49.2% | ||
| -$26.44M-39.2% | -$19M+14.6% | -$22.26M-16.6% | -$19.09M-48.1% | ||
| -$1.32-18.9% | -$1.11+22.4% | -$1.43+4.7% | -$1.50+49.0% | ||
| -$27.57M-38.9% | -$19.85M+13.3% | -$22.9M-19.0% | -$19.23M-49.2% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Is Nuvectis Pharma, Inc. profitable?
- Nuvectis Pharma, Inc. is not currently profitable: it reported a net loss of $27.2M over the trailing twelve months.
- What is Nuvectis Pharma, Inc.'s earnings per share?
- Nuvectis Pharma, Inc.'s diluted EPS over the trailing twelve months is $-1.31.
- Where does Nuvectis Pharma, Inc.'s income statement data come from?
- Every line is extracted from Nuvectis Pharma, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.